We are live on ! Find out more
VRDN icon

Viridian Therapeutics

235 hedge funds and large institutions have $2.83B invested in Viridian Therapeutics in 2026 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 84 increasing their positions, 63 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

33% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 63

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

13% more capital inflows, than outflows

Capital inflows: $402M | Capital outflows: $358M

8% more funds holding

Funds holding: 217 → 235 (+18)

11.94% less ownership

Funds ownership: 133.11% → 121.18% (-12%)

72% less call options, than puts

Call options by funds: $3.3M | Put options by funds: $11.6M

Holders
235
Holders Change
+18
Holders Change %
+8.29%
% of All Funds
2.86%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.1%
New
44
Increased
84
Reduced
63
Closed
23
Calls
$3.3​M
Puts
$11.6​M
Net Calls
-⁠$8.33​M
Net Calls Change
-⁠$14.9​M

VRDN Hedge Fund Activity: Q3 2026 in Review

235 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2026, worth a combined $2.83B — up 13% from $2.5B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VRDN positions and 23 closed out — a net gain of 21 holders — while 84 added to existing stakes and 63 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $105M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $43.8M sold.

  • 235 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2026, up from 217 in Q2 2026.
  • Funds reported $2.83B of Viridian Therapeutics stock for Q3 2026, up 13% quarter-over-quarter.
  • 44 funds opened new Viridian Therapeutics positions in Q3 2026 and 23 closed out, a net change of +21 holders.
  • The largest Viridian Therapeutics buyer in Q3 2026 was RTW Investments, an estimated $105M added.
  • The largest Viridian Therapeutics seller in Q3 2026 was Baker Bros. Advisors, an estimated $43.8M sold.

Based on aggregated 13F filings for Q3 2026.